Researchers
have discovered a new compound that could potentially treat migraines
by blocking light sensors in the eyes, according to a study published in
the journal Nature Chemical Biology.
Researchers from the Salk Institute for
Biological Studies have found that a series of compounds called
opsinamides can block a receptor in the eye called melanopsin – a
receptor found in neurons connecting the eyes and the brain.
The researchers discovered 10 years ago
that melanopsin is responsible for sensing light on its own, away from
normal vision. Continued research found that this receptor is
responsible for maintaining sleep cycles and various other sensitivity
functions in those with healthy vision.
The receptor was also found to be
responsible for constricting the pupil within the eye when it is exposed
to bright light, triggering the light-sensitivity that is commonly
linked to migraines.
The receptor also picks up on
light-sensitivity as we sleep, explaining why sleep patterns can be
disrupted if exposed to artificial light during the night.
From this discovery, the researchers
believed that if they could find a way to block melanopsin, treatments
could be created to prevent and treat migraines.
However, there are other receptors that
are closely related to melanopsin – rhodopsin and cone opsins – which
are responsible for processing visual information to the brain.
Therefore, the researchers needed to create a drug that blocked
melanopsin but did not interfere with the other receptors.
Opsinamides successful in mice study
For their latest study, the researchers
analyzed hundreds of chemicals from the Lundbeck library to see whether
each chemical would block melanopsin, and they measured the calcium
levels when the receptors were exposed to light.
Researchers say the new drug blocks the melanopsin receptor responsible for light-sensitivity associated with migraines.






0 comments:
Post a Comment